Approval · Notice of Compliance 31896 · 2023
RYBELSUS: Notice of Compliance 31896
Issued October 19, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31896
- Date
- October 19, 2023
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional drug substance manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RYBELSUS | Not yet assigned | — |
Medicinal ingredients
- SEMAGLUTIDE 3 MG per TAB
- SEMAGLUTIDE 7 MG per TAB
- SEMAGLUTIDE 14 MG per TAB